All News
Filter News
Found 239 articles
-
SpringWorks Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights
8/4/2022
SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, reported second quarter financial results for the period ended June 30, 2022 and provided an update on recent company developments.
-
SpringWorks Therapeutics to Present at the 2022 Wedbush PacGrow Healthcare Conference
8/2/2022
SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in a fireside chat at the 2022 Wedbush PacGrow Healthcare Conference on Wednesday, August 10th at 10:55 a.m. ET.
-
SpringWorks Therapeutics Appoints Carlos Albán to its Board of Directors
7/15/2022
SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced the appointment of Carlos Albán to the Company’s Board of Directors.
-
SpringWorks Therapeutics to Present Progress Across the Company’s Targeted Oncology Portfolio at Virtual R&D Day
6/10/2022
SpringWorks Therapeutics, Inc., announced that the Company will host a virtual R&D Day , Friday, June 10th from 10:00 a.m. to 1:00 p.m. ET.
-
SpringWorks Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
6/9/2022
SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference.
-
Precision BioSciences Provides Update on Allogeneic CAR T Programs and Path Forward with Its Lead PBCAR0191 Candidate for CAR T Relapsed Patient Population
6/8/2022
PBCAR0191 Achieved 100% Response Rate (ORR), 73% Complete Response (CR) Rate and 50% Durable Response Greater than Six Months Among Evaluable CAR T Relapsed Subjects.
-
Mirati Therapeutics presented the first clinical data demonstrating CNS-specific activity of a KRASG12C inhibitor in patients with NSCLC with active and untreated CNS metastases.
-
A roundup of last week's top clinical trial announcements and news, including updates from Pfizer, BioNTech, Ocugen and more.
-
Mirati Therapeutics' adagrasib is going up against Amgen’s Lumakras in the KRAS race, and according to Friday pre-market trading, the results shared Thursday don't seem to be enough for investors.
-
Emergence Of Multispecific Antibodies Targeted Therapies Market
5/26/2022
Multispecific Antibodies Cumulative Sales Have Already Surpassed USD 9 Billion By 2021 Says Kuick Research In Recent Reports On Bispecific & Trispecific Antibodies.
-
SpringWorks Therapeutics Highlights Nirogacestat Clinical Data at the 2022 ASCO Annual Meeting
5/26/2022
SpringWorks Therapeutics, Inc. announced initial clinical data from the Phase 1/2 study evaluating nirogacestat, SpringWorks’ investigational gamma secretase inhibitor, in combination with BLENREP, GSK plc’s antibody drug conjugate targeting B-cell maturation agent, in patients with relapsed or refractory multiple myeloma.
-
SpringWorks Therapeutics Announces Nirogacestat Achieved Primary and All Key Secondary Endpoints in Phase 3 DeFi Trial in Adult Patients with Progressing Desmoid Tumors
5/24/2022
SpringWorks Therapeutics, Inc. announced positive topline results from the DeFi trial, a double-blind, placebo-controlled Phase 3 trial evaluating the efficacy, safety and tolerability of nirogacestat, an investigational oral gamma secretase inhibitor, in adult patients with progressing desmoid tumors.
-
B Cell Maturation Antigen Targeted Therapy Clinical Trials Report 2026
5/20/2022
B-cell maturation target (BCMA) has recently emerged out as potential target for the development of novel immunotherapies in multiple myeloma.
-
SpringWorks Therapeutics to Host Virtual R&D Day on June 10, 2022
5/16/2022
SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that it will host a virtual R&D Day for investors and analysts on Friday, June 10, 2022 at 10:00 am ET.
-
Precision BioSciences Reports First Quarter 2022 Financial Results and Provides Business Update
5/9/2022
Precision BioSciences, Inc. today announced financial results for the first quarter ended March 31, 2022 and provided a business update.
-
SpringWorks Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights
5/5/2022
SpringWorks Therapeutics, Inc reported first quarter financial results for the period ended March 31, 2022 and provided an update on recent company developments.
-
Despite the loss of its COVID-19 antibody, REGEN-COV, earlier this year, Regeneron posted a positive first quarter driven primarily by sales of Dupixent and Eylea.
-
Regeneron Augments I-O Portfolio with Checkmate, Partners with SpringWorks on Multiple Myeloma
4/19/2022
Regeneron announced it has acquired Checkmate Pharmaceuticals and that it has entered a clinical trial collaboration with SpringWorks Therapeutics to treat multiple myeloma. -
SpringWorks Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Regeneron to Evaluate Nirogacestat in Combination with REGN5458 in Patients with Relapsed or Refractory Multiple Myeloma
4/19/2022
SpringWorks Therapeutics, Inc. announced that the company has entered into a clinical trial collaboration and supply agreement with Regeneron Pharmaceuticals, Inc. to evaluate nirogacestat, SpringWorks’ investigational gamma secretase inhibitor, in combination with Regeneron’s investigational bispecific antibody targeting B-cell maturation antigen and CD3, REGN5458, in patients with relapsed or refractory multiple myeloma.
-
Allogene Therapeutics Announces Preclinical Publication Highlighting Superiority of Healthy Donor-Derived Allogeneic CAR T Cells Over Patient-Derived Cells in Multiple Myeloma
3/23/2022
Allogene Therapeutics, Inc. (Nasdaq: ALLO), today announced the publication of preclinical study results demonstrating the superior long-term in vitro myeloma-killing activity of allogeneic anti-BCMA CAR T cells from healthy donors compared with anti-BCMA CAR T cells from patients with multiple myeloma.